Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517) - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2015

Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517)

Yves Bertrand
  • Function : Author
  • PersonId : 899520
Nicolas Blin
Emmanuelle Tavernier
  • Function : Author
Francoise Mazingue
  • Function : Author
Genevieve Plat
  • Function : Author
José Fernandes
  • Function : Author
Luc Fornecker
  • Function : Author
Thibault Leguay
  • Function : Author
Alina Ferster
Cecile Bonin
  • Function : Author
Yann Godfrin
  • Function : Author
Iman El Hariry
  • Function : Author

Abstract

Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015
Not file

Dates and versions

hal-01290438 , version 1 (18-03-2016)

Identifiers

  • HAL Id : hal-01290438 , version 1

Cite

Yves Bertrand, André Baruchel, Xavier Thomas, Nicolas Blin, Emmanuelle Tavernier, et al.. Evaluation of the Impact of the Presence of Neutralizing L-Asparaginase Antibodies on the Efficacy and Safety of Graspa in Phase 3 Randomized Trial Versus Native L-Asparaginase in Patients with Relapsed Acute Lymphoblastic Leukemia (NCT01518517). Blood, 2015, 126 (23), pp.3734. ⟨hal-01290438⟩
175 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More